Upcoming Type C meeting

Hi All,

As some would have seen, IMU recieved positive type C meeting minutes this morning with the FDA granted a move from ph1b straight to ph3.

This shows the new direction and relaxation of strict requirements and steps for new drugs in highly unmet groups as per previous AI news post.

Although it didnt rocket the SP, it shows the FDA is serious.

Given that, I hope they open the door for Alterity to move into ph2 studies of PD and AD when they line up for the type C end of ph2 trial meeting.